AbbVie and Alphabet company commit $1bn to collaboration
AbbVie and Alphabet have committed a further $1 billion to fund Alphabet-backed Calico’s development of new therapies for patients with age-related diseases.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 February 2021 AbbVie and its Korean partner Medytox have settled a trade secret dispute with competitor Evolus over the sale of a rival botox competitor drug Jeuveau.
6 April 2021 Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission.
23 February 2021 AbbVie and its Korean partner Medytox have settled a trade secret dispute with competitor Evolus over the sale of a rival botox competitor drug Jeuveau.
6 April 2021 Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission.
23 February 2021 AbbVie and its Korean partner Medytox have settled a trade secret dispute with competitor Evolus over the sale of a rival botox competitor drug Jeuveau.
6 April 2021 Pharmaceutical companies defending an antitrust lawsuit have fought back against attempts to get them to disclose confidential information garnered through discovery during the litigation to the US Federal Trade Commission.
